间充质干细胞作为携带miR-124a外泌体的天然生物工厂用于胶质瘤治疗
研究筛选8种miR对胶质瘤干细胞的作用,发现miR-124a最有效;将miR-124a转导至骨髓间充质干细胞,分离出携带miR-124a的外泌体(Exo-miR124),体外可降低胶质瘤干细胞活力和克隆形成能力,体内使50%颅内胶质瘤干细胞267模型小鼠长期存活,机制为沉默FOXA2导致脂质异常积累。
要点
- miR-124a在筛选中对胶质瘤干细胞最有效。
- 间充质干细胞可包装miR-124a至外泌体,Exo-miR124体外降低胶质瘤干细胞活力和克隆形成。
- Exo-miR124系统给药使50%颅内胶质瘤干细胞267小鼠长期存活。
核心结论
- 间充质干细胞可作为天然生物工厂生产Exo-miR124,后者是值得进一步临床评估的有效抗胶质瘤药物。
研究设计与样本
- 基于文献检索选择8种miR,在代表癌症基因组图谱定义的全部胶质母细胞瘤亚型的胶质瘤干细胞系中进行筛选。
- 将miR-124a转导至体外培养的骨髓间充质干细胞,从培养基中分离外泌体,并在体外和颅内胶质瘤干细胞267小鼠模型中测试。
主要发现
- 筛选的miR中,miR-124a被确定为对胶质瘤干细胞最有效的抗胶质瘤药物。
- 电子显微镜、蛋白质印迹和Nanosight证实分离的囊泡为外泌体,定量PCR显示其含高水平miR-124a,而对照外泌体不含miR-124a。
- 体外用含miR-124a的外泌体(Exo-miR124)处理胶质瘤干细胞,与对照相比活力和克隆形成能力显著降低。
- 颅内胶质瘤干细胞267小鼠经系统给药Exo-miR124后,50%的动物长期存活,存活者组织学分析未见肿瘤证据。
- 机制研究显示miR-124a通过沉默叉头框(FOX)A2发挥作用,导致细胞内脂质异常积累。
临床怎么用
- 作者认为间充质干细胞可作为天然生物工厂生产Exo-miR124,该药是值得进一步临床评估的有效抗胶质瘤药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MicroRNAs (miRs) are promising new therapeutics for glioblastoma. However, which miRs are most effective against glioblastomas and how these miRs should be delivered are major unanswered problems. METHODS: To identify potent antiglioma miRs, we selected 8 miRs based on a literature search and screened them against a panel of glioma stem cell (GSC) lines, representing all of the glioblastoma subtypes defined by The Cancer Genome Atlas. To address delivery, we tested the hypothesis that ex vivo cultured bone marrow-derived mesenchymal stem cells (MSCs) can package miRs into exosomes and that these engineered exosomes can systemically deliver antiglioma miRs to glioblastomas. RESULTS: Of the screened miRs, we identified miR-124a as the most effective antiglioma agent against GSCs. We then transduced MSCs with lentivirus vectors containing miR-124a and isolated vesicles from the medium. Electron microscopy, western blotting, and Nanosight proved that the isolated vesicles were exosomes. Quantitative PCR documented that these exosomes contained high levels of miR-124a, which was not present in control exosomes. In vitro treatment of GSCs with exosomes containing miR-124a (Exo-miR124) resulted in a significant reduction in viability and clonogenicity of GSCs compared with controls. In vivo treatment of mice harboring intracranial GSC267 with systemically delivered Exo-miR124 resulted in 50% of animals living long term. No evidence of tumor was present on histological analysis of the survivors. Mechanistic studies showed that miR-124a acts by silencing Forkhead box (FOX)A2, resulting in aberrant intracellular lipid accumulation. CONCLUSION: MSCs can be used as natural biofactories to produce Exo-miR124, which is an effective antiglioma agent worthy of further clinical evaluation.
引用
- Lang FM, Hossain A, Gumin J, et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro Oncol. 2018. PMID: 29016843. doi:10.1093/neuonc/nox152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。